Lead Product(s): Conestat alfa
Therapeutic Area: Infections and Infectious Diseases
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Following treatment with RUCONEST®, fever resolved in four of the five patients within 48 hours, and laboratory markers of inflammation decreased significantly (CRP, IL-6).